Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
The methods for treatment of advanced prostate cancer, based on the agonistic analogs of LH-RH were reviewed. New therapeutic approaches utilizing antagonistic analogs of LH-RH such as SB-75 (Cetrorelix) have been described. Analogs of LH-RH chemically linked to various cytotoxic radicals are also being developed. Combinations of LH-RH agonists or antagonists with superactive somatostatin analogues such as Octastatin (RC-160) or with bombesin/GRP antagonists are being investigated in order to delay or prevent the relapse and improve the therapy for prostate cancer.
Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112.
A V
AV
Schally
A M
AM
Comaru-Schally
D
D
Gonzalez-Barcena
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001839:Bombesin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; C051458:vapreotide; D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; C062876:cetrorelix; D001839:Bombesin